Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Genzyme |
---|---|
Information provided by: | Genzyme |
ClinicalTrials.gov Identifier: | NCT00445302 |
Eligible male and female subjects with renal impairment (aged 18-78 years) and healthy control subjects (aged in the upper age range of the renal impairment subjects) will be enrolled in the study. Subjects with renal impairment will be enrolled and entered into three groups based on their renal function: Mild Impairment, Moderate Impairment, and Severe Impairment(not requiring dialysis). Control subjects will have normal renal function.
The screening visits will occur 14 days prior to AMD3100 administration on study day one. Subjects will be monitored for 10 hours following administration of the study drug. In addition, subjects will return to the clinic at 24 and 48 hours after AMD3100 administration for blood samples and safety assessments.
Condition | Intervention | Phase |
---|---|---|
Renal Impairment |
Drug: AMD3100 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase I Study Of The Safety, Pharmacokinetics, And Hematological Activity Of AMD3100 (240 µg/kg) In Subjects With Renal Impairment |
Estimated Enrollment: | 18 |
Study Start Date: | January 2006 |
Study Completion Date: | August 2007 |
This is a phase I, open label, multi-center study in which up to eighteen subjects with renal impairment and six healthy control subjects with normal renal function will receive a single dose of AMD3100 (240 µg/kg) administered by subcutaneous (SC) injection.
Eligible male and female subjects with renal impairment (aged 18-78 years) and healthy control subjects (aged in the upper age range of the renal impairment subjects) will be enrolled in the study. Subjects with renal impairment will be enrolled and stratified into three cohorts using their Screening 24 hour urine collection to measured creatinine clearance (CLcr) values (an estimate of Glomerular Filtration Rate): Mild Impairment (CLcr = 51-80 ml/min), Moderate Impairment (CLcr = 31-50 ml/min), and Severe Impairment (CLcr <31 ml/min, not requiring dialysis). Control subjects will have normal renal function (CLcr >90 ml/min), as determined by a Screening 24 hour urine collection.
The screening visits will occur 14 days prior to AMD3100 administration on study day one. Subjects will be monitored for 10 hours following administration of the study drug. In addition, subjects will return to the clinic at 24 and 48 hours after AMD3100 administration for blood samples and safety assessments.
Ages Eligible for Study: | 18 Years to 78 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Apex Research of Riverside | |
Santa Ana, California, United States, 92705 | |
United States, Nebraska | |
Creighton University Medical Center | |
OMAHA, Nebraska, United States, 68131 |
Study ID Numbers: | AMD31001101 |
Study First Received: | March 7, 2007 |
Last Updated: | June 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00445302 History of Changes |
Health Authority: | United States: Food and Drug Administration |
AMD3100 |
Anti-HIV Agents Anti-Retroviral Agents JM 3100 Antiviral Agents |
Anti-Infective Agents Anti-HIV Agents Anti-Retroviral Agents JM 3100 |
Therapeutic Uses Antiviral Agents Pharmacologic Actions |